Lithium Orotate (Low-Dose) — Supplements

Overview

Low-dose lithium orotate occupies a unique position between a longevity supplement and a pharmaceutical. Lithium carbonate/citrate is FDA-approved for bipolar disorder at 600–1,800 mg/day (delivering ~112–338 mg elemental lithium), with a narrow therapeutic window and well-characterized toxicity. Lithium orotate — a salt form with higher CNS bioavailability — is used at 1–10 mg/day (delivering ~0.2–2 mg elemental lithium), doses 100–1,000× lower than psychiatric doses. The scientific case for low-dose lithium as a neuroprotective and longevity compound rests on multiple lines of evidence. Landmark epidemiological studies (Nunes et al., 2007; Kessing et al., 2010; Schrauzer & Shrestha, 1990) have found that populations with naturally higher lithium content in drinking water have significantly lower rates of Alzheimer's disease dementia, suicide, and all-cause mortality — effects observed at lithium levels as low as 10–150 µg/L, far below any therapeutic psychiatric dose. A 2013 Brazilian RCT (Nunes et al., British Journal of Psychiatry, n=45, 15 months) found lithium 150 µg/day (micro-dose) significantly slowed cognitive decline in amnestic mild cognitive impairment compared to placebo — the first interventional human trial of ultra-low-dose lithium for neuroprotection. Mechanistically, low-dose lithium inhibits GSK-3β, a key enzyme in tau phosphorylation and neuroinflammation, and increases BDNF expression — providing a plausible explanation for the epidemiological and clinical observations.

Indications

• Neuroprotection and dementia prevention (epidemiological and emerging RCT evidence)
• Mild cognitive impairment (ultra-low dose — 150 µg/day study)
• Mood stabilization at sub-psychiatric doses (emerging evidence)
• Impulsivity and aggression reduction
• Lithium-deficiency correction in populations with low drinking water lithium

Mechanism of Action

Lithium's primary molecular mechanism is potent inhibition of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase that phosphorylates tau protein (promoting neurofibrillary tangle formation in Alzheimer's disease), activates NF-κB neuroinflammation, and suppresses CREB-mediated neuroprotective gene transcription. GSK-3β inhibition is the leading mechanistic explanation for lithium's anti-dementia properties

Dosing

Evidence Grade

GRADE C

Safety & Contraindications

• At 1–10 mg elemental lithium/day, lithium orotate is far below the therapeutic psychiatric dose and below the threshold for renal, thyroid, or cardiac toxicity associated with pharmaceutical lithium
• Lithium orotate is NOT equivalent to prescription lithium carbonate — do not use as a substitute for psychiatric lithium without medical supervision
• At even low-dose supplemental levels, lithium can affect thyroid function (TSH elevation) and kidney function in some individuals — periodic monitoring recommended
• Do not combine with NSAIDs (increase lithium levels), ACE inhibitors, or diuretics without monitoring (all increase lithium reabsorption)
• Avoid in pregnancy — lithium is a known teratogen (Ebstein's anomaly risk) even at low doses
• Monitor hydration — lithium reabsorption increases with dehydration; maintain adequate fluid intake
• Signs of excess (though unlikely at orotate doses): tremor, nausea, cognitive dulling — discontinue and check serum levels
• Serum lithium monitoring is technically available but levels from low-dose orotate are typically undetectable — clinical monitoring is symptom-based